Study on the effectiveness of COVID-19 measures in the Netherlands The measures implemented in the Netherlands during the COVID-19 crisis were effective against the spread of the SARS-CoV-2 virus. This is the outcome of a study conducted by RIVM.
Growth of digital healthcare stabilised in 2023 The growth in the use of digital healthcare tools by care providers stabilised in 2023. This was mainly because most care providers were already using particular digital tools in 2022, such as the patient portal – on which patients can view the outcomes of examinations – and e-consultations (digital written contact with doctors).
Pneumonia increase likely caused by multiple viruses and bacteria More patients with pneumonia visited their GP from August 2023 on than in previous years. The rise in cases of pneumonia among children, adolescents and young adults aged 5–25 years is particularly notable.
Respiratory infections widespread, even more important to follow recommendations The number of people in the Netherlands with respiratory symptoms continues to increase. Besides COVID-19 and rhinovirus, the number of people who have flu is also increasing. We are also seeing more and more people with pneumonia. Some of these cases are caused by the bacteria Mycoplasma pneumoniae.
Respiratory infections now in season More and more people are coughing and sneezing, although it is not an epidemic at this point. The season in which respiratory infections circulate in the Netherlands has now started. There are various viruses that can cause respiratory infections.
Participation rates in cancer population screening programmes continue to decline The number of participants in the population screening programmes for breast cancer, cervical cancer and colorectal cancer continues to decline. This decline has been going on for years, reaching its lowest point in 2020.
Metabolic disorder ALD added to newborn blood spot screening Since 1 October, the metabolic disorder adrenoleukodystrophy (ALD) has been added to the Dutch newborn blood spot screening. From now on, the blood of newborn boys will also be tested for this disorder. ALD in boys can be treated if it is detected in time.
COVID-19 vaccination for risk groups: over-60s, flu vaccine group, care workers and pregnant women From 19 September 2023 on, the first people will receive an invitation for COVID-19 vaccination. The first invitations will be sent by RIVM to people aged 60 years and older.
From 1 October 2023, heel prick test also screens for metabolic disorder ALD From 1 October 2023, the blood of newborn babies will also be tested for the metabolic disorder adrenoleukodystrophy (ALD). This is done with the heel prick screening test.
NIPT available as standard option for all pregnant women from 1 April From 1 April 2023, the Non-Invasive Prenatal Test (NIPT) will be available to all pregnant women. They do not have to take part in a scientific study for this.